Mepro-analgesic

Mepro-analgesic Brand names, Mepro-analgesic Analogs

Mepro-analgesic Brand Names Mixture

No information avaliable

Mepro-analgesic Chemical_Formula

C₂₀H₂₃NS

Mepro-analgesic RX_link

No information avaliable

Mepro-analgesic fda sheet

Mepro-analgesic msds (material safety sheet)

Mepro-analgesic Synthesis Reference

No information avaliable

Mepro-analgesic Molecular Weight

309.469 g/mol

Mepro-analgesic Melting Point

< 25 ^oC

Mepro-analgesic H₂O Solubility

Soluble as HCl salt

Mepro-analgesic State

Liquid

Mepro-analgesic LogP

5.7

Mepro-analgesic Dosage Forms

Tablets (oral, 1 mg)

Mepro-analgesic Indication

Used for the symptomatic treatment of parkinsonism.

Mepro-analgesic Pharmacology

Metixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.

Mepro-analgesic Absorption

Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.

Mepro-analgesic side effects and Toxicity

Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.

Mepro-analgesic Patient Information

Mepro-analgesic Organisms Affected

Humans and other mammals